Gilead Sciences (GILD) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Gilead Sciences · Health Care · ref. ETF XLV · 51 calls · price $148.86
What the company does: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
📈 Gilead Sciences (GILD) stock price
$148.86+32.2% over range
Aug 28, 25low $110.56 · high $155.8Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
73% recommend buying · 11 analysts
📊 JPI status : Gilead Sciences is no longer in our current JPI rankings, but appeared in the past (2021, 2017, 2015) — its upside may be behind it. See the stocks picked in 2021 →
🎯 GILD price target & analyst consensus — price $149
The price target · all analysts combined (11 targets)
Highest target · 1 firm of 11$180+20.9%
Median target · of 11 targets$156+4.8%
Lowest target · 1 firm of 11$123-17.4%
Current price$148.86
Where these 11 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
873%
$155 ↔ $180
Below
327%
$123 ↔ $145
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $165 (+11 %), call made on July 28, 2026, maturing on July 28, 2027 (31 d ago).
The 5 reliable analysts
$156+4.8 %
The 6 other firms
$160+7.5 %
How to read it: the 5 reliable firms are not filtered by optimism — 3 aim above the price, 2 below, hence their $156 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 11 ratings (last 6 months)
Strong Buy00%
Buy873%
Hold327%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 GILD price target all
All 12 calls, one by one, with our verdict on each firm.
→ See all 12 targets, analyst by analyst💡 The best analysts on GILD most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in GILD? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Gilead Sciences? The JPI assistant answers using our backtest data.
💰 Gilead Sciences dividend: yield, history & growth › open the full page
2.56%annual yield
📈 Steady dividend — 10 yrs of consecutive dividend increases
That's ~$3.22 per share per year.
📈 Gilead Sciences fundamentals: valuation, margins & growth › open the full page
P/E —Net margin -10.6 %Revenue growth +10.2 %Not (yet) profitable
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 17 %
2023
Rev −1%Profit +23%
2024
Rev +6%Profit −92%
2025
Rev +2%Profit +1673%
🔎 Detailed analyses
🏛️ Which US Congress members hold Gilead Sciences (GILD)?
4 Congress members have disclosed GILD buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
✅ Historical analyst reliability on GILD
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Baird ↗ | 100% | +60.6% | 2 |
| CFRA | 100% | +21.6% | 2 |
| Berenberg ↗ | 100% | +4.7% | 2 |
| Deutsche Bank ↗ | 92% | +51.3% | 13 |
| JP Morgan ↗ | 90% | +35.0% | 10 |
| UBS ↗ | 89% | +61.1% | 9 |
| Nomura | 86% | +27.2% | 7 |
| Wells Fargo ↗ | 86% | +26.0% | 7 |
| Stifel ↗ | 83% | +72.5% | 6 |
| B of A Securities ↗ | 83% | +30.0% | 6 |
See the other 19 firms
| Cantor Fitzgerald ↗ | 40% | -3.8% | 5 |
| SVB Leerink | 43% | +0.5% | 7 |
| Raymond James ↗ | 43% | +8.3% | 7 |
| Citigroup ↗ | 44% | +8.9% | 9 |
| Redburn Partners | 50% | -1.8% | 2 |
| Credit Suisse | 50% | +7.0% | 10 |
| Leerink Swann | 50% | +9.8% | 2 |
| Barclays ↗ | 50% | +21.0% | 10 |
| Oppenheimer ↗ | 57% | +11.6% | 14 |
| Mizuho ↗ | 57% | +19.3% | 7 |
| RBC Capital ↗ | 60% | +6.5% | 10 |
| Piper Sandler ↗ | 60% | +23.7% | 15 |
| Jefferies ↗ | 67% | -2.1% | 3 |
| Truist Securities ↗ | 67% | +5.3% | 3 |
| Argus Research ↗ | 67% | +22.3% | 3 |
| Morgan Stanley ↗ | 69% | +23.1% | 13 |
| Maxim Group | 75% | +10.9% | 4 |
| BMO Capital ↗ | 79% | +28.9% | 14 |
| Bernstein ↗ | 80% | +32.7% | 5 |
📊 What $1,000 invested in Gilead Sciences would be worth › open the full page
In short — $1,000 invested in Gilead Sciences 10 years ago would be worth $1,249 today, i.e. +2%/yr on average. Best year: 2025 (+33%), worst: 2016 (-29%). Price performance, excluding dividends.
If I'd invested $1,000 in Gilead Sciences
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,368 | +37% |
| 3 years ago | $1,472 | +47% |
| 5 years ago | $2,169 | +117% |
Return by year (Gilead Sciences)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +3% | $1,029 (+3%) |
| 2025 | +33% | $1,368 (+37%) |
| 2024 | +14% | $1,560 (+56%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Gilead Sciences
Loading news…
📋 All analyst calls on GILD
Filtered on — · ✕ show all
RBC Capital ↗
Aug 5, 26
■ Sector Perform neutral · not a buy · 🎯$123
Price at call : $130.86 — gap to target -6%
Today : $148.86 — gap to target -17%
🎯 on GILD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
Cantor Fitzgerald ↗
Aug 5, 26
▲ Overweight · 🎯$155
Price at call : $131.76 — upside +18%
Today : $148.86 — upside +4%
🎯 on GILD : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
▲ Buy · 🎯$170
Price at call : $131.76 — upside +29%
Today : $148.86 — upside +14%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
■ Equal-Weight neutral · not a buy · 🎯$145
Price at call : $132.73 — gap to target +9%
Today : $148.86 — gap to target -3%
🎯 on GILD : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
Morgan Stanley ↗
Jul 27, 26
▲ Overweight · 🎯$165
Price at call : $134.32 — upside +23%
Today : $148.86 — upside +11%
🎯 on GILD : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 27, 27
matures : Jul 27, 27
Leerink Partners ↗
Jul 21, 26
■ Market Perform neutral · not a buy · 🎯$127
Price at call : $130.34 — gap to target -3%
Today : $148.86 — gap to target -15%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Jul 21, 27
matures : Jul 21, 27
Morgan Stanley ↗
Jul 8, 26
▲ Overweight · 🎯$166
Price at call : $134.84 — upside +23%
Today : $148.86 — upside +12%
🎯 on GILD : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
RBC Capital ↗
Jul 7, 26
■ Sector Perform neutral · not a buy · 🎯$120
Price at call : $135.82 — gap to target -12%
Today : $148.86 — gap to target -19%
🎯 on GILD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
See the other 43 calls, newest to oldest
Truist Securities ↗
Jul 7, 26
▲ Buy · 🎯$156
Price at call : $136.36 — upside +14%
Today : $148.86 — upside +5%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
Cantor Fitzgerald ↗
Jul 6, 26
▲ Overweight · 🎯$155
Price at call : $129.61 — upside +20%
Today : $148.86 — upside +4%
🎯 on GILD : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
▲ Buy · 🎯$155
Price at call : $129.61 — upside +20%
Today : $148.86 — upside +4%
🎯 on GILD : no call matured yet · 📊 on Health : 53.6% · +1.4% (28 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
Cantor Fitzgerald ↗
Jun 16, 26
▲ Overweight · 🎯$155
Price at call : $127.23 — upside +22%
Today : $148.86 — upside +4%
🎯 on GILD : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jun 16, 27
matures : Jun 16, 27
Maxim Group
May 20, 26
▲ Buy · 🎯$165
Price at call : $130.69 — upside +26%
Today : $148.86 — upside +11%
🎯 on GILD : no call matured yet · 📊 unranked overall
in progress (365j)
matures : May 20, 27
matures : May 20, 27
Truist Securities ↗
May 8, 26
▲ Buy · 🎯$157
Price at call : $133.52 — upside +18%
Today : $148.86 — upside +5%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : May 8, 27
matures : May 8, 27
RBC Capital ↗
May 8, 26
■ Sector Perform neutral · not a buy · 🎯$122
Price at call : $133.52 — gap to target -9%
Today : $148.86 — gap to target -18%
🎯 on GILD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 8, 27
matures : May 8, 27
▲ Buy · 🎯$165
Price at call : $140.45 — upside +17%
Today : $148.86 — upside +11%
🎯 on GILD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
Morgan Stanley ↗
Apr 10, 26
▲ Overweight · 🎯$175
Price at call : $139.03 — upside +26%
Today : $148.86 — upside +18%
🎯 on GILD : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 10, 27
matures : Apr 10, 27
▲ Buy · 🎯$180
Price at call : $146 — upside +23%
Today : $148.86 — upside +21%
🎯 on GILD : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
▲ Buy · 🎯$170
Price at call : $147.64 — upside +15%
Today : $148.86 — upside +14%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Feb 23, 27
matures : Feb 23, 27
■ Equal-Weight neutral · not a buy · 🎯$155
Price at call : $149.83 — gap to target +3%
Today : $148.86 — gap to target +4%
🎯 on GILD : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
RBC Capital ↗
Feb 11, 26
■ Sector Perform neutral · not a buy · 🎯$118
Price at call : $151.81 — gap to target -22%
Today : $148.86 — gap to target -21%
🎯 on GILD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Truist Securities ↗
Feb 11, 26
▲ Buy · 🎯$152
Price at call : $151.81 — upside +0%
Today : $148.86 — upside +2%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Wells Fargo ↗
Feb 11, 26
▲ Overweight · 🎯$165
Price at call : $151.81 — upside +9%
Today : $148.86 — upside +11%
🎯 on GILD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Cantor Fitzgerald ↗
Feb 11, 26
▲ Overweight · 🎯$155
Price at call : $155.8 — upside -1%
Today : $148.86 — upside +4%
🎯 on GILD : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Scotiabank ↗
Feb 11, 26
▲ Sector Outperform · 🎯$177
Price at call : $155.8 — upside +14%
Today : $148.86 — upside +19%
🎯 on GILD : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
▲ Buy · 🎯$170
Price at call : $155.8 — upside +9%
Today : $148.86 — upside +14%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Truist Securities ↗
Jan 27, 26
▲ Buy · 🎯$145
Price at call : $139.72 — upside +4%
Today : $148.86 — upside -3%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
▲ Buy · 🎯$156
Price at call : $139.72 — upside +12%
Today : $148.86 — upside +5%
🎯 on GILD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
▲ Buy · 🎯$155
Price at call : $140.97 — upside +10%
Today : $148.86 — upside +4%
🎯 on GILD : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jan 26, 27
matures : Jan 26, 27
Morgan Stanley ↗
Jan 13, 26
▲ Overweight · 🎯$150
Price at call : $124.07 — upside +21%
Today : $148.86 — upside +1%
🎯 on GILD : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jan 13, 27
matures : Jan 13, 27
▲ Buy · 🎯$140
Price at call : $120.67 — upside +16%
Today : $148.86 — upside -6%
🎯 on GILD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 7, 27
matures : Jan 7, 27
Morgan Stanley ↗
Dec 12, 25
▲ Overweight · 🎯$151
Price at call : $119.78 — upside +26%
Today : $148.86 — upside +1%
🎯 on GILD : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
Wells Fargo ↗
Dec 10, 25
▲ Overweight · 🎯$150
Price at call : $123.21 — upside +22%
Today : $148.86 — upside +1%
🎯 on GILD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Dec 10, 26
matures : Dec 10, 26
▲ Buy · 🎯$140
Price at call : $125.02 — upside +12%
Today : $148.86 — upside -6%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Nov 13, 26
matures : Nov 13, 26
Scotiabank ↗
Nov 13, 25
▲ Sector Outperform · 🎯$140
Price at call : $125.2 — upside +12%
Today : $148.86 — upside -6%
🎯 on GILD : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Nov 13, 26
matures : Nov 13, 26
Truist Securities ↗
Nov 3, 25
▲ Buy · 🎯$145
Price at call : $123 — upside +18%
Today : $148.86 — upside -3%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Nov 3, 26
matures : Nov 3, 26
Wells Fargo ↗
Oct 31, 25
▲ Overweight · 🎯$145
Price at call : $122.05 — upside +19%
Today : $148.86 — upside -3%
🎯 on GILD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
▲ Overweight · 🎯$150
Price at call : $122.05 — upside +23%
Today : $148.86 — upside +1%
🎯 on GILD : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
RBC Capital ↗
Oct 31, 25
■ Sector Perform neutral · not a buy · 🎯$105
Price at call : $122.05 — gap to target -14%
Today : $148.86 — gap to target -29%
🎯 on GILD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
Cantor Fitzgerald ↗
Oct 31, 25
▲ Overweight · 🎯$135
Price at call : $122.05 — upside +11%
Today : $148.86 — upside -9%
🎯 on GILD : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
▲ Buy · 🎯$133
Price at call : $119.79 — upside +11%
Today : $148.86 — upside -11%
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
▲ Buy · 🎯$125
Price at call : $120.94 — upside +3%
Today : $148.86 — upside -16%
🎯 on GILD : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Oct 23, 26
matures : Oct 23, 26
▲ Buy · 🎯$135
Price at call : $116.74 — upside +16%
Today : $148.86 — upside -9%
🎯 on GILD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Oct 8, 26
matures : Oct 8, 26
▲ Overweight · 🎯$145
Price at call : $110.86 — upside +31%
Today : $148.86 — upside -3%
🎯 on GILD : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Sep 16, 26
matures : Sep 16, 26
BMO Capital ↗
Aug 8, 25
▲ Outperform · 🎯$130
Price at call : $120.47 — upside +8%
Today : $148.86 — upside -13%
Expected +8% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 60.7% · +8.8% (239 calls)
+10.4%
stock +10% · XLV +29%
matured Aug 8, 26
RBC Capital ↗
Aug 8, 25
■ Sector Perform neutral · not a buy · 🎯$98
Price at call : $120.47 — gap to target -19%
Today : $148.86 — gap to target -34%
🎯 on GILD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 8, 26
matures : Aug 8, 26
■ Neutral neutral · not a buy · 🎯$112
Price at call : $120.47 — gap to target -7%
Today : $148.86 — gap to target -25%
🎯 on GILD : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Aug 8, 26
matures : Aug 8, 26
Truist Securities ↗
Aug 8, 25
▲ Buy · 🎯$127
Price at call : $119.41 — upside +6%
Today : $148.86 — upside -15%
Expected +6% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
+11.4%
stock +11% · XLV +29%
matured Aug 8, 26
▲ Buy · 🎯$133
Price at call : $116.2 — upside +14%
Today : $148.86 — upside -11%
Expected +14% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 50.3% · +4.1% (155 calls)
+12.3%
stock +12% · XLV +20%
matured Jul 25, 26
■ Hold neutral · not a buy
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : May 21, 26
matures : May 21, 26
Leerink Partners ↗
Oct 21, 24
▲ Outperform · 🎯$96
Price at call : $86.29 — upside +11%
Today : $148.86 — upside -36%
Expected +11% · Actual +44% · Reason (≥ +15%) : ✓ Yes
🎯 on GILD : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
+43.8%
stock +44% · XLV -4%
matured Oct 21, 25
Frequently asked questions
Should I buy Gilead Sciences stock?
This isn't buy advice. For Gilead Sciences, the analyst consensus is "Buy", with an average price target of $156 (+5% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Gilead Sciences). We show the numbers — you decide.
Is it too late to buy Gilead Sciences? How high can it go?
The most bullish analyst target on Gilead Sciences is $180 (+21% above today's price); the average is $156. That's the upside they see. Check how reliable those analysts have actually been on Gilead Sciences on our site before trusting it.
Is Gilead Sciences still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 29 analysts have a real record on Gilead Sciences, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Gilead Sciences? The case for and against
The arguments for and against, one by one, from the numbers: why invest in GILD (and why hesitate).
What has Gilead Sciences's past performance been?
Historical returns and a "how much if I had invested" calculator: GILD performance & returns.
Does Gilead Sciences pay a dividend?
Yield, consistency and growth history of the dividend: GILD's dividend.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX